Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a national referral hospital in Sierra Leone, 2017 to 2022: A retrospective cohort study

Sierra Leone is one of the 30 high TB burden countries in the world, with an incidence rate in 2023 of 273 per 100,000 population. Despite progress in case notification and treatment coverage, around 5,000 cases of TB in Sierra Leone are missing each year. The COVID-19 pandemic has further compounded these challenges. We highlight its effect on drug-resistant TB treatment outcomes. We conducted a retrospective cohort study of drug-resistant TB cases using national data from January 2017 to December 2022. Data was analyzed using STATA. Descriptive analysis summarized demographic, clinical characteristics and treatment outcomes. Logistic regression examined the association between time-period and outcomes, adjusting for age, gender, nutritional status, HIV status and regimen. Of 701 patients, 383 (54.6%) were registered pre-COVID-19, 228 (32.5%) during, and 92 (13.1%) post-COVID-19. Pre-treatment TB cases reduced from 359 (92.5%) in the pre-COVID-19 period to 80 (30.9%) in the COVID-19 period. New treatment cases increased from 29 (7.5%) to 159 (61.4%) during COVID-19. Treatment completion decreased from 74.7% pre-COVID-19 to 63.3% during and 68.5% post-COVID-19). Malnourished patients had higher odds of success (aOR: 1.482, 95% CI: 1.007-2.183), while those on short regimen had lower odds (aOR: 0.51, 95% CI: 0.321-0.810). We observed a decline in drug-resistant TB treatment success rate during COVID-19, which was primarily influenced by concurrent shifts in treatment protocols and underlying secular trends. The pandemic itself did not emerge as an independent determinant of poor treatment outcomes, highlighting the resilience of the TB care system. Nonetheless, the pandemic had significant indirect consequences, including worsening rates of malnutrition and HIV co-infection. These trends point to deeper systemic vulnerabilities, such as weak social protection mechanisms, increased food insecurity, and disruptions in HIV service delivery, all of which contributed to delay in diagnosis and compromised treatment adherence.

Authors

Institutions

Publication Details

Journal
PLOS Global Public Health
Published
2026-03-04
DOI
https://doi.org/10.1371/journal.pgph.0004472
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a national referral hospital in Sierra Leone, 2017 to 2022: A retrospective cohort study

Stephen Sevalie, Mariama Mahmoud, Bailah Molleh, Josephine Amie Koroma et al.
PLOS Global Public Health
Tuberculosis Research and Epidemiology
article

Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a national referral hospital in Sierra Leone, 2017 to 2022: A retrospective cohort study

Stephen Sevalie, Mariama Mahmoud, Bailah Molleh, Josephine Amie Koroma, Sulaiman Lakoh, Joseph Sam Kanu, Adrienne K. Chan, Sharmistha Mishra
article en

Abstract

Sierra Leone is one of the 30 high TB burden countries in the world, with an incidence rate in 2023 of 273 per 100,000 population. Despite progress in case notification and treatment coverage, around 5,000 cases of TB in Sierra Leone are missing each year. The COVID-19 pandemic has further compounded these challenges. We highlight its effect on drug-resistant TB treatment outcomes. We conducted a retrospective cohort study of drug-resistant TB cases using national data from January 2017 to December 2022. Data was analyzed using STATA. Descriptive analysis summarized demographic, clinical characteristics and treatment outcomes. Logistic regression examined the association between time-period and outcomes, adjusting for age, gender, nutritional status, HIV status and regimen. Of 701 patients, 383 (54.6%) were registered pre-COVID-19, 228 (32.5%) during, and 92 (13.1%) post-COVID-19. Pre-treatment TB cases reduced from 359 (92.5%) in the pre-COVID-19 period to 80 (30.9%) in the COVID-19 period. New treatment cases increased from 29 (7.5%) to 159 (61.4%) during COVID-19. Treatment completion decreased from 74.7% pre-COVID-19 to 63.3% during and 68.5% post-COVID-19). Malnourished patients had higher odds of success (aOR: 1.482, 95% CI: 1.007-2.183), while those on short regimen had lower odds (aOR: 0.51, 95% CI: 0.321-0.810). We observed a decline in drug-resistant TB treatment success rate during COVID-19, which was primarily influenced by concurrent shifts in treatment protocols and underlying secular trends. The pandemic itself did not emerge as an independent determinant of poor treatment outcomes, highlighting the resilience of the TB care system. Nonetheless, the pandemic had significant indirect consequences, including worsening rates of malnutrition and HIV co-infection. These trends point to deeper systemic vulnerabilities, such as weak social protection mechanisms, increased food insecurity, and disruptions in HIV service delivery, all of which contributed to delay in diagnosis and compromised treatment adherence.

PLOS Global Public HealthVol. 6(3)
University of Sierra Leone (SL), University of Toronto (CA), Sierra Leone Urban Research Centre (SL), Sustainable Energy Systems (United Kingdom) (GB)
Zero hunger
Openalex Percentile: Top 35%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.